Open AccessS738 Re-Induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn’s Disease
Author(s) -
Scott D. Lee,
Kendra Kamp,
Kindra ClarkSnustad
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776484.37297.38
Subject(s) - medicine , ustekinumab , adverse effect , crohn's disease , dosing , maintenance therapy , surgery , disease , chemotherapy , infliximab